Last reviewed · How we verify
Bleomycin + Fibrovein
Bleomycin is a chemotherapeutic antibiotic that damages DNA, while Fibrovein is a fibrin-based hemostatic agent used to control bleeding during surgical application of bleomycin.
Bleomycin is a chemotherapeutic antibiotic that damages DNA, while Fibrovein is a fibrin-based hemostatic agent used to control bleeding during surgical application of bleomycin. Used for Intraoperative hemostasis and local chemotherapy delivery during cancer surgery.
At a glance
| Generic name | Bleomycin + Fibrovein |
|---|---|
| Also known as | Bleomycin Baxter + Fibrovein pharmaceutical products |
| Sponsor | Oslo University Hospital |
| Drug class | Chemotherapy agent with hemostatic adjuvant |
| Target | DNA (bleomycin); fibrin polymerization (fibrovein) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Bleomycin intercalates into DNA and causes strand breaks, leading to cell death in rapidly dividing cancer cells. Fibrovein is a topical hemostatic agent composed of fibrinogen and thrombin that promotes clotting. This combination is used intraoperatively to deliver bleomycin while simultaneously controlling hemorrhage at the surgical site.
Approved indications
- Intraoperative hemostasis and local chemotherapy delivery during cancer surgery
Common side effects
- Pulmonary fibrosis
- Skin toxicity
- Mucositis
- Hematologic toxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bleomycin + Fibrovein CI brief — competitive landscape report
- Bleomycin + Fibrovein updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI